EANS-Adhoc: Intercell AG provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Company Information

16.10.2012

» Preliminary, unaudited third quarter close shows approximately EUR
18m IXIARO®/JESPECT® sales for the nine months ended September 30th
2012 - representing significant growth compared to EUR 15.5m sales in
the same period of 2011

» However, previous sales growth expectations had been higher and
full year sales and net loss expectations are therefore lowered by
10% to 20%

Vienna, October 16, 2012 - Intercell AG (VSE: ICLL) today announced
an adjustment of its product sales expectations for IXIARO®/JESPECT®,
a vaccine to prevent Japanese Encephalitis, and expected full year
net loss ahead of its Q3 2012 financial results announcement,
scheduled for November 7th, 2012.

Following an analysis of recent vaccine adoption trends and the
expected order intake for the rest of the year, Intercell now expects
2012 IXIARO®/JESPECT® sales growth of EUR 5m to 7m, resulting in
expected product sales between EUR 26.5m and 28.5m for the full year
2012 (2011: EUR 21.6m). The company also updated the range of its
expected full year net loss to EUR 20m to 24m. For the nine months
ended September 30th, 2012, Intercell expects to report a net loss of
approximately EUR 14.5m to 15m.

Based on the expected orders and demand, and subject to timely
product release to secure supply of the vaccine, the revised full
year product sales expectation assumes strong Q4 sales of EUR 8.5m to
10.5m (Q4 2011: EUR 6.1m) underscoring the unlocked potential of this
vaccine.

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English